JP5855018B2 - 腫瘍細胞増殖を阻害するための改善された組成物 - Google Patents

腫瘍細胞増殖を阻害するための改善された組成物 Download PDF

Info

Publication number
JP5855018B2
JP5855018B2 JP2012552394A JP2012552394A JP5855018B2 JP 5855018 B2 JP5855018 B2 JP 5855018B2 JP 2012552394 A JP2012552394 A JP 2012552394A JP 2012552394 A JP2012552394 A JP 2012552394A JP 5855018 B2 JP5855018 B2 JP 5855018B2
Authority
JP
Japan
Prior art keywords
tumor
cancer
mature
cells
inflammatory
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2012552394A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013519363A (ja
JP2013519363A5 (cg-RX-API-DMAC7.html
Inventor
アレックス カールソン−パラ
アレックス カールソン−パラ
ベント アンデション
ベント アンデション
アンナカリン ヴァルグレン
アンナカリン ヴァルグレン
Original Assignee
イミュニカム アーベー
イミュニカム アーベー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by イミュニカム アーベー, イミュニカム アーベー filed Critical イミュニカム アーベー
Publication of JP2013519363A publication Critical patent/JP2013519363A/ja
Publication of JP2013519363A5 publication Critical patent/JP2013519363A5/ja
Application granted granted Critical
Publication of JP5855018B2 publication Critical patent/JP5855018B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/45—Bacterial antigens
    • A61K40/4532—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Developmental Biology & Embryology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2012552394A 2010-02-10 2011-02-10 腫瘍細胞増殖を阻害するための改善された組成物 Expired - Fee Related JP5855018B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US30315310P 2010-02-10 2010-02-10
US61/303,153 2010-02-10
SE1050133-6 2010-02-10
SE1050133 2010-02-10
PCT/EP2011/051952 WO2011098516A1 (en) 2010-02-10 2011-02-10 Improved composition for inhibiting tumor cell proliferation

Publications (3)

Publication Number Publication Date
JP2013519363A JP2013519363A (ja) 2013-05-30
JP2013519363A5 JP2013519363A5 (cg-RX-API-DMAC7.html) 2014-03-06
JP5855018B2 true JP5855018B2 (ja) 2016-02-09

Family

ID=43903832

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012552394A Expired - Fee Related JP5855018B2 (ja) 2010-02-10 2011-02-10 腫瘍細胞増殖を阻害するための改善された組成物

Country Status (13)

Country Link
US (1) US9034317B2 (cg-RX-API-DMAC7.html)
EP (1) EP2534242B1 (cg-RX-API-DMAC7.html)
JP (1) JP5855018B2 (cg-RX-API-DMAC7.html)
KR (1) KR101770785B1 (cg-RX-API-DMAC7.html)
CN (1) CN102782123B (cg-RX-API-DMAC7.html)
BR (1) BR112012019267B1 (cg-RX-API-DMAC7.html)
DK (1) DK2534242T3 (cg-RX-API-DMAC7.html)
ES (1) ES2581277T3 (cg-RX-API-DMAC7.html)
HU (1) HUE028352T2 (cg-RX-API-DMAC7.html)
PL (1) PL2534242T3 (cg-RX-API-DMAC7.html)
RU (1) RU2565542C2 (cg-RX-API-DMAC7.html)
SI (1) SI2534242T1 (cg-RX-API-DMAC7.html)
WO (1) WO2011098516A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2668816C2 (ru) * 2012-12-18 2018-10-02 Иммуникум Аб Совместная дифференцировка моноцитов от аллогенных доноров
PT3291821T (pt) * 2015-05-07 2026-03-18 Baylor College Medicine Imunoterapêutica com células dendríticas
CN105462926A (zh) * 2015-12-31 2016-04-06 深圳市中美康士生物科技有限公司 一种免疫细胞瘤苗的制备方法及其应用
CN105695403A (zh) * 2015-12-31 2016-06-22 深圳市中美康士生物科技有限公司 一种杀伤性免疫细胞的培养方法及其应用
CN107574149B (zh) * 2016-07-05 2022-02-18 上海细胞治疗研究院 一种树突状细胞的促成熟方法及其用途
CN106085960A (zh) * 2016-07-28 2016-11-09 广州赛莱拉干细胞科技股份有限公司 一种培养dc细胞的培养基及培养方法
EP3516045A1 (en) * 2016-09-23 2019-07-31 The United States of America, as represented by The Secretary, Department of Health and Human Services Methods of preparing an isolated population of dendritic cells and methods of treating cancer using same
GB201711379D0 (en) 2017-07-14 2017-08-30 Univ Cape Town Maturation of dendritic cells
HUE047540T2 (hu) * 2017-09-20 2020-04-28 Immunicum Ab Javított allogén dendritikus sejtek rák kezelésében történõ alkalmazásra

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040214783A1 (en) * 2002-05-08 2004-10-28 Terman David S. Compositions and methods for treatment of neoplastic disease
CN102600461B (zh) * 2002-12-06 2017-07-14 西北生物治疗药物公司 给予体外部分成熟的树突细胞治疗肿瘤
EP1840206A1 (en) 2006-03-28 2007-10-03 Gsf-Forschungszentrum Für Umwelt Und Gesundheit, Gmbh Compositions for the preparation of mature dendritic cells
WO2008110569A1 (en) * 2007-03-12 2008-09-18 Bioneer A/S Method for determination of immunomodulatory effect
JP2010539993A (ja) * 2007-10-08 2010-12-24 イントレキソン コーポレーション 遺伝子操作した樹状細胞および癌の治療のための使用
US8728806B2 (en) * 2008-12-06 2014-05-20 The Board Of Regents, The University Of Texas System Methods and compositions related to Th-1 dendritic cells
CN101481677B (zh) * 2009-01-22 2011-12-14 复旦大学附属华山医院 体外刺激树突状细胞成熟的方法

Also Published As

Publication number Publication date
RU2012137173A (ru) 2014-03-20
US9034317B2 (en) 2015-05-19
KR101770785B1 (ko) 2017-08-23
US20120328662A1 (en) 2012-12-27
ES2581277T3 (es) 2016-09-05
EP2534242A1 (en) 2012-12-19
CN102782123A (zh) 2012-11-14
SI2534242T1 (sl) 2016-08-31
JP2013519363A (ja) 2013-05-30
EP2534242B1 (en) 2016-04-20
DK2534242T3 (en) 2016-07-18
BR112012019267B1 (pt) 2022-03-03
PL2534242T3 (pl) 2016-11-30
WO2011098516A1 (en) 2011-08-18
KR20120114358A (ko) 2012-10-16
HUE028352T2 (en) 2016-12-28
CN102782123B (zh) 2016-05-11
BR112012019267A2 (pt) 2020-10-06
RU2565542C2 (ru) 2015-10-20

Similar Documents

Publication Publication Date Title
JP2013519363A (ja) 腫瘍細胞増殖を阻害するための改善された組成物
Murray et al. In situ vaccination with cowpea vs tobacco mosaic virus against melanoma
Liau et al. Treatment of intracranial gliomas with bone marrow—derived dendritic cells pulsed with tumor antigens
JP5919226B2 (ja) 抗原負荷した樹状細胞ワクチンを前駆体から発生させる迅速ワンステップ法
JP2022023061A (ja) 樹状細胞を産生するための組成物及び方法
JP6615148B2 (ja) 免疫療法を用いたil−12の誘導
JP2018537478A (ja) 小分子アブレーション化合物を用いたがん免疫治療のための生体外(Ex Vivo:エクスビボ)での免疫細胞活性の増強方法
US10597732B2 (en) Allogeneic autophagosome-enriched composition for the treatment of disease
CA2991212A1 (en) Compositions and methods for combination therapy with dengue virus and dendritic cells
Hwang et al. Generation of Potent Cytotoxic T Lymphocytes Against Castration‐Resistant Prostate Cancer Cells by Dendritic Cells Loaded With Dying Allogeneic Prostate Cancer Cells
US10716810B2 (en) Canine autologous immunotherapy using dendritic cell induced cancer killing immunocytes
Pham Regulation of memory CD8 T cell differentiation
Ishii et al. Application of NKT Cells in Immunotherapy
US20120076827A1 (en) Compositions and methods for generating an immune response in a subject
HK1089336A (en) Rapid one-step method for generation of antigen loaded dendritic cell vaccine from precursors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140116

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140116

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150407

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150707

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20151117

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20151208

R150 Certificate of patent or registration of utility model

Ref document number: 5855018

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees